Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5479599 with carboplatin and paclitaxel in first-line advanced squamous NSCLC
NL-OMON41018Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumretuzumab, carboplatin, paclitaxel in Pulmonary squamous cell carcinoma, sponsored by Roche. Started Nov 2014; status: active, not recruiting.
02
Drugs
lumretuzumabcarboplatinpaclitaxel
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON41018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41018.